Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04025840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Jul 2024 to Oct 22, 2024
    • Study completion date: Jul 2026 to Nov 2026
    • Site details revised
    v5
  2. Collaborators expanded, about 14 wordsv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2019 to Sep 11, 2019
    • Site details revised
    v3
  4. Start date: Jul 2019 to Sep 2019v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pancreatic cancer remains a devastating disease with an average 5-year survival rate of about 3-5%. Previous retrospective studies showed that perioperative epidural block and/or dexamethasone are associated with improved outcome after cancer surgery. This randomized trial aims to investigate the effect of perioperative epidural block and/or dexamethasone on long-term survival in patients following pancreatic cancer surgery.
Trial Details
NCT Number NCT04025840
Lead Sponsor Peking University First Hospital
Collaborators: Peking University Cancer Hospital & Institute, The Second Affiliated Hospital of Chongqing Medical University
Conditions
(from sponsor)		 Pancreatic Cancer, Surgery, Epidural Block, Dexamethasone, Overall Survival
Related terms Pancreatic Neoplasms
Enrollment 260 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov